Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | HMGCR | P04035 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL8309128 | 0.91 | CYP4F2 (0.35) | CYP4F2CYP4A11HMGCRCA1CA2 | |
| SCHEMBL17860722 | 0.84 | CYP4F2 (0.36) | CYP4F2CYP4A11HMGCR | |
| SCHEMBL130722 | 0.82 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1LMNAHSD17B10 | |
| SCHEMBL5021627 | 0.82 | CYP4F2 (0.41) | CYP4F2CYP4A11HMGCRALDH1A1LMNA | |
| SCHEMBL824523 | 0.82 | CYP4F2 (0.41) | CYP4F2CYP4A11HMGCRALDH1A1 | |
| SCHEMBL13296226 | 0.80 | CYP4F2 (0.39) | CYP4F2CYP4A11HMGCRALDH1A1LMNA | |
| SCHEMBL1628655 | 0.80 | CYP4F2 (0.44) | CYP4F2CYP4A11HMGCRALDH1A1LMNA | |
| Ammonia Solution, Strong SCHEMBL27912168 | 0.80 | CYP4F2 (0.53) | CYP4F2CYP4A11ALDH1A1LMNAHSD17B10 | |
| SCHEMBL13039891 | 0.80 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1LMNAHSD17B10 | |
| SCHEMBL248949 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521711-B1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES PHARMA IRELAND LTD (IE) | 2017-08-16 | — | — | EP | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| EP-2521711-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | Alkermes, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011084846-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084850-A1 | PRODRUGS FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISEASE | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084851-A1 | ASENAPINE PRODURUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| CN-1043042-C | Cephalosporins derivatives and process for preparing them | HOECHST AG (DE) | 1999-04-21 | — | — | CN | disclosed |
| US-RE34865-E | Antibiotics | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-02-21 | — | — | US | disclosed |
| US-5100887-A | Bactericides | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-03-31 | — | — | US | disclosed |
| CN-1035509-A | Cynnematin analog derivative and preparation method thereof | HOECHST AG (DE) | 1989-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | CYP4F2 2146/4885CYP4A11 1424/4885HMGCR 3269/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | CYP4F2 2028/4885CYP4A11 571/4885HMGCR 2456/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | CYP4F2 173/4885CYP4A11 749/4885HMGCR 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.